Chicago biotech argues bluebird, Third Rock 'killed' its rival, pioneering thalassemia gene therapy in lawsuit
Bluebird bio $BLUE chief Nick Leschly courted controversy last week when he revealed the company’s beta thalassemia treatment will carry a jaw-dropping $1.8 million price tag over a 5-year period in Europe — making it the planet’s second most expensive therapy behind Novartis’ $NVS freshly approved spinal muscular atrophy therapy, Zolgensma, at $2.1 million. A Chicago biotech, meanwhile, has been fuming at the sidelines. In a lawsuit filed earlier this month, Errant Gene Therapeutics alleged that bluebird and venture capital group Third Rock unlawfully prised a viral vector, developed in partnership with the Memorial Sloan Kettering Cancer Center (MSK), from its grasp, and thwarted the development of its seminal gene therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.